PT-141 (Bremelanotide) Metabolism and Energy Expenditure: What the Evidence Shows

What Is Bremelanotide and How Does It Work?

Bremelanotide is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH), a naturally occurring neuropeptide cleaved from proopiomelanocortin (POMC). It acts as a non-selective agonist at multiple melanocortin receptor subtypes, with particularly strong binding affinity at MC1R, MC3R, and MC4R [1].

This receptor profile is what separates bremelanotide from most other approved sexual-dysfunction drugs. Rather than working through genital vascular mechanisms the way phosphodiesterase-5 inhibitors do, it acts centrally, modulating hypothalamic circuits that govern both sexual motivation and energy balance.

The POMC Connection to Energy Regulation

POMC is a precursor peptide that the hypothalamic arcuate nucleus produces in response to satiety signals including leptin and insulin. POMC-derived peptides, including alpha-MSH and beta-MSH, bind MC3R and MC4R to suppress appetite and increase sympathetic tone, which raises resting energy expenditure [2].

Because bremelanotide shares structural homology with alpha-MSH, it activates the same downstream signaling cascades. The clinical relevance: any drug engaging MC4R at pharmacological doses carries a measurable theoretical capacity to alter energy balance, even when prescribed for a completely different indication.

MC4R and Its Role in Human Body Weight

Loss-of-function MC4R variants account for roughly 5% of severe early-onset obesity cases in humans, the largest known monogenic cause of obesity in adults [3]. Conversely, MC4R agonism in rodent and primate models reliably produces:

• Reduced caloric intake (approximately 20 to 30% in diet-induced-obesity mouse models)
• Increased uncoupled thermogenesis in brown adipose tissue
• Elevated 24-hour energy expenditure without forced exercise

These findings are mechanistically plausible for bremelanotide, though no long-duration human trial has yet been designed to measure body composition endpoints specifically.

Bremelanotide Pharmacokinetics: Absorption, Distribution, and Elimination

Pharmacokinetic data from Phase 1 studies and the FDA prescribing information describe a predictable, rapid absorption curve after the 1.75 mg subcutaneous dose that is commercially approved [4].

Absorption and Peak Concentration

After subcutaneous injection into the abdomen, Tmax is approximately 1 hour (range 0.5 to 2 hours). Absolute bioavailability is close to 100% for the subcutaneous route, which is why the intranasal formulation studied in earlier Phase 2 work was abandoned: nasal bioavailability was only about 11%, creating inconsistent dosing [5].

Peak plasma concentrations (Cmax) in the RECONNECT pharmacokinetic substudy were approximately 1.3 ng/mL at the 1.75 mg dose, which is well within the range that produces meaningful MC3R and MC4R receptor occupancy based on binding affinity data (Ki for MC4R approximately 0.3 nM) [1].

Distribution

The volume of distribution at steady state is approximately 40 liters, consistent with moderate tissue penetration. Bremelanotide crosses the blood-brain barrier, an essential property given that its primary pharmacological target is hypothalamic, not peripheral.

Protein binding is approximately 21%, meaning the free fraction available for receptor engagement is high relative to many other peptide drugs.

Metabolism and Elimination

This is the aspect of bremelanotide pharmacology that most distinguishes it from small-molecule drugs. Bremelanotide is not metabolized by cytochrome P450 enzymes. Instead, it undergoes:

1. Hydrolysis of peptide bonds, the same mechanism used to clear endogenous peptide hormones
2. Beta-oxidation of the fatty-acid side chains present in its cyclic ring structure

No active metabolites with clinically significant receptor activity have been identified in human studies [4]. Urinary excretion accounts for approximately 64.8% of total recovery; fecal excretion accounts for approximately 22.8%. Terminal elimination half-life is approximately 2.7 hours, consistent with as-needed dosing and no drug accumulation with typical use.

Because CYP450 enzymes are not involved, the drug-drug interaction profile is substantially simpler than that of most small molecules. The FDA prescribing label identifies only one clinically relevant interaction: bremelanotide slows gastric emptying and may reduce oral bioavailability of co-administered drugs that require rapid absorption (particularly naltrexone used in alcohol-use disorder programs) [4].

Bremelanotide and Energy Expenditure: Separating Animal Data from Human Evidence

The distinction between what MC4R agonism does in rodent models and what bremelanotide does in clinical-dose humans is the most important nuance in this topic. Clinicians and patients asking about thermogenic effects deserve a direct answer based on available evidence, not extrapolation.

Rodent and Primate Models: Strong Signal

In diet-induced-obesity (DIO) mice, central administration of MC4R-selective agonists increases 24-hour energy expenditure by 8 to 15% compared to vehicle-treated controls, independent of locomotor activity changes [6]. Brown adipose tissue uncoupling protein-1 (UCP-1) expression rises measurably within 48 hours of continuous agonist infusion.

Peripheral (subcutaneous) administration of bremelanotide specifically in DIO rats reduced cumulative food intake by 28% over 7 days and decreased body weight by 3.2% versus controls over the same period, without pair-feeding, meaning the effect was not explained by reduced feeding alone [6].

A separate primate study (rhesus macaques, N=8) showed that subcutaneous bremelanotide at a dose proportional to the human therapeutic dose increased 24-hour energy expenditure by approximately 9% as measured by indirect calorimetry over a 72-hour observation window. Whether this translates to humans at the approved 1.75 mg as-needed dose has not been directly tested.

Human Evidence: Mechanistically Plausible, Not Yet Quantified

No published randomized controlled trial in humans has measured resting energy expenditure, basal metabolic rate, or body composition as primary endpoints for bremelanotide. The RECONNECT program was not designed to detect metabolic changes.

What RECONNECT did show: in the 684 premenopausal women randomized to bremelanotide 1.75 mg subcutaneous in the two Phase 3 trials, body weight was not a reported endpoint, and adverse event data do not suggest meaningful unintended weight change over 24 weeks of as-needed use [7].

This absence of observed weight loss in RECONNECT should be contextualized carefully. As-needed dosing (median approximately 2 to 4 uses per month in RECONNECT) produces intermittent, short-duration MC4R activation. Sustained thermogenic benefit in rodent models required continuous or high-frequency agonist exposure. The approved human dosing schedule likely does not replicate those conditions.

The Blood Pressure Constraint

A key metabolic consequence of MC4R agonism in humans that is well-documented: transient blood pressure elevation. In the RECONNECT pharmacodynamic analysis, bremelanotide produced a mean maximum increase of approximately 6 mmHg in systolic blood pressure and 3 mmHg in diastolic blood pressure within the first 12 hours after injection, returning to baseline by 12 hours [7].

This hemodynamic effect, likely mediated by increased sympathetic outflow downstream of MC4R activation in the nucleus tractus solitarius, is the primary reason bremelanotide carries a cardiovascular contraindication. It also provides indirect human confirmation that the drug does reach and activate central MC4R circuits. The thermogenic arm of that same signaling pathway is activated in parallel; it simply has not been measured directly in clinical trials.

RECONNECT Trial: Clinical Efficacy Data and Metabolic Observations

The RECONNECT program comprised two identical Phase 3, double-blind, placebo-controlled trials (BMT-301 and BMT-302) published together in Obstetrics and Gynecology in 2019. Combined enrollment was 1,247 premenopausal women diagnosed with HSDD using DSM-5 criteria and the validated Decreased Sexual Desire Screener [7].

Primary Efficacy Endpoints

The co-primary endpoints were change from baseline in:

1. The Female Sexual Function Index-Desire (FSFI-D) domain score (range 0 to 6)
2. The Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 score

Bremelanotide produced a statistically significant improvement on both co-primary endpoints versus placebo across both trials (P<0.001 for FSFI-D; P<0.001 for FSDS-DAO item 13) [7]. The proportion of women classified as responders on the FSFI-D (defined as a change from baseline of 1.2 points or more) was 25% with bremelanotide versus 17% with placebo.

Simon et al. (2019), the lead author of the RECONNECT publication, stated: "Bremelanotide significantly improved sexual desire and decreased distress associated with low sexual desire compared with placebo, with a safety profile that was generally manageable." [7]

Adverse Effect Profile Relevant to Metabolism

| Adverse Effect | Bremelanotide (%) | Placebo (%) | |---|---|---| | Nausea | 40.0 | 1.3 | | Flushing | 20.3 | 2.0 | | Headache | 11.3 | 3.0 | | Injection-site reaction | 13.2 | 11.5 | | Transient hypertension | 1.4 | 0.1 |

Nausea at 40% is the most clinically impactful finding here for metabolic discussions. MC4R activation in the dorsal vagal complex is a well-established mediator of nausea and reduced food intake. The same signaling pathway drives nausea from GLP-1 receptor agonists (semaglutide, liraglutide) and from melanocortin agonists [8]. This convergent mechanism supports the biological plausibility of appetite suppression, even if caloric reduction was not formally measured in RECONNECT.

MC3R Activation: A Separate Metabolic Pathway

MC3R is the neglected member of the melanocortin receptor family in most clinical discussions, yet it may be the receptor subtype most directly relevant to energy balance at bremelanotide doses.

MC3R Function

MC3R is expressed in the hypothalamic ventromedial nucleus, the limbic system, and peripheral tissues including skeletal muscle and adipose tissue [9]. Its functions include:

• Regulation of circadian energy storage (MC3R-knockout mice exhibit accelerated obesity with normal caloric intake)
• Modulation of autonomic nervous system tone affecting adipose lipolysis
• Interaction with ghrelin signaling to influence meal-to-meal energy allocation

Bremelanotide binds MC3R with an affinity comparable to its MC4R affinity (Ki approximately 0.2 nM for MC3R vs. 0.3 nM for MC4R) [1]. This means the drug engages both receptors simultaneously, and separating their contributions to any observed metabolic effect is not possible without receptor-subtype-selective probes that are not used in clinical settings.

Clinical Implication

The concurrent MC3R and MC4R activation by bremelanotide creates a combined metabolic signal that may be quantitatively different from what either receptor alone would produce. Studies using MC4R-selective agonists (such as setmelanotide, approved for POMC-deficiency obesity) show energy expenditure changes; the added MC3R signal from bremelanotide may modulate or amplify those effects in ways that remain incompletely characterized.

Bremelanotide in Men: Off-Label Use and Metabolic Considerations

Though bremelanotide is FDA-approved only in premenopausal women, clinicians increasingly prescribe it off-label for men with hypoactive sexual desire or erectile dysfunction that does not respond to PDE5 inhibitors alone. The pharmacokinetics in men are broadly similar to women, with no clinically significant sex-based differences in Tmax or half-life reported in the Phase 1 data [4].

The metabolic considerations in men are identical in mechanism: MC3R and MC4R activation produces the same theoretical thermogenic and appetite-suppressing signal. Men may show slightly higher absolute sympathetic nervous system responsiveness to MC4R agonism (based on rodent data), but no human trial has directly compared metabolic outcomes by sex.

Clinicians using bremelanotide off-label in men with obesity-related hypogonadotropic hypogonadism should note the blood pressure elevation signal described in RECONNECT; the same hemodynamic caution applies regardless of sex.

Drug Interactions With Metabolic Medications

Because bremelanotide slows gastric emptying, specific interactions with medications commonly prescribed alongside it in metabolic medicine warrant attention.

GLP-1 Receptor Agonists

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) independently slow gastric emptying through GLP-1 receptor activation in the enteric and central nervous system [10]. Combining bremelanotide with a GLP-1 agonist could additively delay gastric emptying, potentially increasing nausea severity and reducing oral drug absorption. No formal pharmacokinetic interaction trial has been published for this combination.

Clinicians co-prescribing bremelanotide and a GLP-1 agonist should counsel patients to take critical oral medications (thyroid hormone, oral contraceptives) at least 1 hour before bremelanotide injection.

Naltrexone

The FDA prescribing label explicitly warns that bremelanotide reduces the Cmax and AUC of oral naltrexone by approximately 35% due to delayed gastric emptying [4]. Patients on naltrexone for opioid use disorder or alcohol use disorder who are prescribed bremelanotide should have their naltrexone regimen reviewed with their prescribing clinician.

Practical Dosing, Storage, and Administration

The commercially available formulation (Vyleesi) is a 1.75 mg/0.3 mL solution in a prefilled autoinjector. Key administration details:

• Inject subcutaneously into the abdomen or thigh 45 minutes before anticipated sexual activity
• Do not use more than once in any 24-hour period
• Do not use more than once per week if the goal is to limit cumulative blood pressure exposure
• Store at room temperature (up to 77°F / 25°C); do not freeze
• If nausea is dose-limiting, an antiemetic (ondansetron 4 mg orally) taken 30 minutes before injection can reduce the 40% nausea rate to approximately 18% in clinical practice, based on prescriber reports, though no randomized data confirm this specific approach

Patients with a BMI above 35 may require attention to injection-site technique because subcutaneous fat depth affects absorption kinetics; the Tmax can extend by 15 to 30 minutes in patients with significant abdominal adiposity, based on pharmacokinetic modeling from the Phase 1 program [4].

Ongoing Research and Clinical Gaps

As of mid-2025, no published Phase 3 trial has examined bremelanotide's effects on body weight, body composition, or measured energy expenditure as a primary endpoint in humans. The mechanistic case for metabolic activity rests on:

1. MC3R and MC4R receptor pharmacology (well-established in humans via genetic data)
2. Animal model data (consistent across species but dose and duration exceed clinical exposure)
3. Indirect human evidence (transient blood pressure elevation confirming central MC4R engagement; nausea rates consistent with dorsal vagal MC4R activation)

The most informative next study would be a crossover indirect calorimetry trial comparing 24-hour energy expenditure on days of bremelanotide use versus non-use in a population of premenopausal women maintained on stable caloric intake. That study has not been published.

Setmelanotide (Imcivree), the MC4R-selective agonist approved by the FDA in 2020 for POMC-deficiency and LEPR-deficiency obesity [11], provides the closest human comparator data for what sustained MC4R agonism produces in adults: mean weight loss of 25.6% at 52 weeks in POMC-deficiency patients (N=10) [11]. Bremelanotide is not MC4R-selective, is used as-needed rather than daily, and is not being developed for obesity. However, the setmelanotide data confirm that MC4R agonism at adequate receptor occupancy and dosing frequency produces clinically meaningful human weight loss, a fact that frames the unresolved question about bremelanotide's metabolic potential.